基準生技有限公司

基準生技有限公司

30-70%的藥物因為癌抗藥而對癌患者無效。全球所有檢驗方法 (CT, MRI, PET, Next Generation DNA Sequencing, common liquid biopsy) 都無法即時驗出癌抗藥,常導致患者病歿及醫療、經濟的巨大損失。本公司全球首創發明” Tumor Signal Transduction-Liquid Biopsy” 可由血液中檢驗出癌訊息傳遞訊號,可早期、即時、靈敏、節省成本的監控各種癌症、各種治癌療法之癌抗藥。也可即時指導癌藥物最佳劑量,降低癌藥物副作用。

30 - 70% treated drugs become ineffective for the cancer patients due to therapy resistance. Current methods (CT, MRI, PET, tissue biopsy, Next Generation DNA Sequencing, common liquid biopsy) are unable to detect cancer therapy resistance in real-time. This often causes patient death and huge Medicare & economic expenses. Our world‘s first invention “Tumor Signal Transduction-Liquid Biopsy” assays tumor cellular signal transduction activity in blood. The product can monitor therapy resistance of all cancer types and all therapy methods, in Real-time, and is Sensitive, Simple, Cost-saving. Our product can also guide optimal drug dose in real-time to reduce side-effects. Other medical methods are unable to do these.